Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

~74 mi. (Tlalpan, Mexico, +247 more cities)

Local Institution

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

anthracycline, +4 more drugs

chemotherapy, +2 more types

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

~74 mi. (Tlalpan, Mexico, +172 more cities)

Local Institution

Urothelial Carcinoma

cisplatin, +3 more drugs

chemotherapy, +1 more type

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

~74 mi. (Tlalpan, Mexico, +84 more cities)

Local Institution

Clear Cell Renal Cell Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

~74 mi. (Cuauhtémoc, Mexico, +163 more cities)

Investigational Site Number :4840003

CEACAM5 Expression

Non-Squamous Non-Small Cell Lung Carcinoma

tusamitamab ravtansine

chemotherapy, +1 more type

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

~76 mi. (Mexico City, Mexico, +192 more cities)

Grupo Medico Camino Sc

ER Positive, +1 more biomarker

Breast Carcinoma

abemaciclib, +1 more drug

hormone therapy, +1 more type

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

~76 mi. (Mexico City, Mexico, +235 more cities)

Instituto Nacional De Cancerologia de Mexico

Prostate Adenocarcinoma

abiraterone, +9 more drugs

hormone therapy, +2 more types

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

~76 mi. (Mexico City, Mexico, +151 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

niraparib, +1 more drug

immunotherapy, +1 more type

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

~76 mi. (Mexico City, Mexico, +180 more cities)

Exelixis Clinical Site #187

Prostate Adenocarcinoma

atezolizumab, +1 more drug

immunotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~76 mi. (Mexico City, Mexico, +184 more cities)

Health Pharma Professional Research S.A. de C.V:

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

~76 mi. (Mexico City, Mexico, +88 more cities)

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

FGFR2 Fusion

Intrahepatic Cholangiocarcinoma

futibatinib

targeted therapy

Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants

~76 mi. (Mexico City, Mexico, +71 more cities)

GSK Investigational Site

Non-Small Cell Lung Carcinoma

cobolimab, +2 more drugs

chemotherapy, +1 more type

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

~76 mi. (Mexico City, Mexico, +49 more cities)

Local Institution

Clear Cell Renal Cell Carcinoma

axitinib, +3 more drugs

immunotherapy, +2 more types